Chugai Pharmaceutical Co Ltd

4519: XTKS (JPN)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|SQLOCK|$?!ZLOCK|YPw>np^

Chugai Pharma: Phase 3 Results for Oral GLP-1 Drug Disappoint Expectations

Eli Lilly reported topline results for Attain-1, one of two phase 3 trials studying orforglipron, a Chugai-discovered drug, as a treatment for obese or overweight patients. Although it met its primary endpoint, the headline efficacy numbers are lower than expectations.

Sponsor Center